Dr. Chade’s laboratory utilizes translational swine models of chronic renovascular disease (RVD), hypertension, chronic kidney disease (CKD), and early-stage of cardiac failure that have been developed and characterized throughout his research career. In his research, he uses unique physiological imaging techniques using multi-detector computerized tomography (MDCT) to non-invasively measure renal regional volume, total renal blood flow, glomerular filtration rate, tubular dynamics, and endothelial function; echocardiography to investigate the impact on cardiac function and structure; and high-resolution micro-CT to study the 3D architecture of the renal and cardiac microcirculation in situ. These integrated techniques allow Dr. Chade to serially follow the time course of the deterioration of the renal and cardiac function with previously unavailable accuracy. Current efforts in Dr. Chade’s laboratory are also devoted to the discovery and development of novel drug-delivery-based therapeutic strategies to protect the renal and cardiac microcirculation in a targeted fashion, offset inflammation at a molecular level, and recover renal and cardiac function in RVD and CKD in a manner that could potentially be applied to humans. Understanding mechanisms of disease, identifying markers, and using targeted interventions could have important ramifications to pinpoint those patients who will benefit from these novel and other available treatments for these diseases.
1030 Hitt Street
Roy Blunt NextGen Precision Health Building
Columbia, MO 65211
- Cardiovascular / renal physiologic imaging
- Microcirculatory function
- Mechanisms of renal and cardiac disease
- Renal involvement in cardiovascular disease
- Mechanisms of cardiac injury in chronic renal disease
- Discovery and development of new therapeutic strategies for chronic renal disease and cardiac failure
Areas of Expertise
- Development of large animal models
- Renovascular disease and chronic kidney disease
- Use of imaging to study renal and cardiac physiology and pathophysiology
- Renal and cardiac microcirculation
- Development of novel therapeutic interventions
- Mechanisms of renal and cardiac injury in chronic renovascular disease
- Chronic kidney disease
- Cardiovascular risk factors
- Role of renal microvascular rarefaction in defining the progression of injury and the outcomes of the kidney in response to treatment
- Role of angiogenesis and inflammatory-mediated mechanisms
- Potential for renal microvessels to service as therapeutic targets
- Stimulation of renal and cardiac angiogenesis and vascular repair via specific targeted interventions using angiogenic cytokines
- Therapeutic development (characterization, pre-clinical testing, toxicity, efficacy) of novel treatments to preserve and recover renal function
- Potential of novel molecular anti-inflammatory interventions to recover the kidney and the heart. Development and application of drug-delivery technologies
Education & Training
2007 Research Associate, Department of Internal Medicine - Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, 55905, USA
2005 Post-doctoral research training, Department of Internal Medicine - Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, 55905, USA
2001 MD-Cardiology, Residency and Fellowship. Hospital Lagomaggiore, Ministerio de Salud y Bienestar Social, Provincia de Mendoza, Argentina. (1997-2001)
1996 MD, Facultad de Ciencias Médicas, Universidad Nacional de Cuyo, Mendoza, Argentina (1990-1996)
1998 - 2001 Hospital Lagomaggiore, Ministerio de Salud y Bienestar Social, Provincia de Mendoza, Argentina
1997 - 1998 Hospital Lagomaggiore, Ministerio de Salud y Bienestar Social, Provincia de Mendoza, Argentina
Awards & Honors
- XV Inter-American Society of Hypertension/National Heart Lung and Blood Institute New Investigator Travel Award. XV Scientific Meeting of the IASH in San Antonio, Texas, April 2003.
- Mayo Clinic Alumni (2003-)
- XVI Inter-American Society of Hypertension/National Heart Lung and Blood Institute (NHLBI) Young Investigator Travel Award. XVI Scientific Meeting of the IASH in Cancun, Mexico, April 2005.
- Finalist of the Cardiovascular Young Investigator’s Forum at the Northwestern University Feinberg School of Medicine. Chicago, IL, October 2005, 2006, and 2008.
- Department of Medicine Outstanding Research Fellow/Special Project Associate Award, 2006.
- Edward C. Kendall Alumni Award for Highly Meritorious Research, Mayo Clinic Alumni Association, 2006.
- American Society of Hypertension Young Scholar Award, 2007.
- Two times winner of the Cardiovascular Young Investigator’s Forum at the Northwestern University Feinberg School of Medicine. Chicago, IL, 2007 and 2008.
- Second place at the Cardiovascular Young Investigator’s Forum at the Northwestern University Feinberg School of Medicine. Chicago, IL, 2009.
- American Physiological Society Renal Research Recognition Award, Experimental Biology Meeting 2008, San Diego, CA, April 2008.
- 2009, 2010, and 2011 Excellence in Research Award, University of Mississippi.
- 2010 Water and Electrolyte Homeostasis Section New Investigator Award (American Physiological Society).
- 2010 Lazaro J. Mandel Young Investigator Award (American Physiological Society)
- 2011 Harry Goldblatt New Investigator Award-American Heart Association-Council of Hypertension
- 2012 International Society of Hypertension New Investigator Award.
- 2013 - Tenure
- Established Investigator Award-American Heart Association (2014-2018)
- Fellow-American Heart Association, Council of Hypertension (2015-)
- 2016 - Full Professor with Tenure
- 2016 Mid-Career Award for Research Excellence-American Heart Association-Council of Hypertension
- 2016 Translational Research Team Award-University of Mississippi Medical Center
- 2022 All-Star Professors – M1: Carl G. Evers Society, University of Mississippi Medical Center
- Chade AR, Eirin, A:
“Cardiac micro-RNA and transcriptomic profile of a novel swine model of chronic kidney disease and left ventricular diastolic dysfunction (CKD-LVDD)”.
Am J Physiol- Heart and Circulatory Physiology, 2022 (In press).
- Rajagopalan KS, Glasstetter LM, Zhy XY, Thaler R, Tang H, Jordan KL, Saadiq IM, Herrmann SM, Chade AR, Irazabal MV, Lerman LO, Eirin, A:
“Renal ischemia induces epigenetic changes in apoptotic, proteolytic, and mitochondrial genes in swine scattered tubular-like cells”.
Cells. 2022 May 31;11(11):1803.
- Chade AR and Bidwell GL:
“Novel Drug Delivery Technologies and Targets for Renal Disease”.
Hypertension. 79(9):1937-1948, 2022.
- Irazabal MV, Chade AR, Eirin, A:
“Chronic renal injury and metabolic derangements: role of mtDNA and mitomiRs”.
Clin Sci (Lond). 2022 Mar 18;136(5):345-36 (Invited review).
- Farahani RA, Yu S, Ferguson CM, Zhu YX, Tang H, Jordan KL, Saadiq IM, Chade AR, Lerman A, Lerman LO, Eirin A:
“Renal revascularization attenuates myocardial mitochondrial damage and improves diastolic function in pigs”.
J Cardiovasc Transl Res. 2022 Feb;15(1):15-26.
- Chade AR, Engel J, Hall ME, Eirin, A, Bidwell GL:
“Intra-renal Modulation of NF-kB Activity Attenuates Cardiac Injury in a Swine Model of CKD: A Renal-Cardio Axis”.
Am J Physiol Renal Physiol 321: F411–F423, 2021.
- Tucci M, Pride Y, Sereduck S, Salazar-Marocho S, Jackson R, Jefferson JR, Chade AR, Grill RJ, Grayson BE:
“Delayed systemic treatment with cannabinoid receptor 2 agonist mitigates spinal cord injury-induced osteoporosis more than treatment directly following injury”.
Neurotrama Reports, 2(1):270-284, 2021.
- Waller JP, Burke S, Engel JE, Chade AR, and Gene L. Bidwell, III:
“Dose-Escalating Toxicology of the Candidate Biologic ELP-VEGF”.
Scientific Reports 11, 6216. 2021.
- Engel JE, Williams ML, Williams E, Azar C, Taylor ER, Bidwell GL, Chade AR:
" Recovery of Renal Function Following Kidney Specific VEGF Therapy in Experimental Renovascular Disease".
American Journal of Nephrology,51(11):891-902, 2020.
- Dalmasso C, Chade AR, Bix GJ, Mendez M, Chen KC, Loria AS:
“Reduction of Intrarenal Angiotensin II Levels in Response to Early Life Stress is Associated with Increased Microvascular Density”
Front Physiol. 11:1046, 2020.
- Chade AR, Williams ML, Engel JE, Williams E, Bidwell GL:
“Molecular Targeting of Renal Inflammation using Drug Delivery Technology to Inhibit NF-kB Improves Renal Recovery in Chronic Kidney Disease”
Am J Physiol Renal Physiol. 319(1):F139-F148. 2020.
- Spradley FT, Ge Y, Chade AR:
"Utero-placental vascular remodeling during late gestation in Sprague-Dawley rats "
Pregnancy Hypertens, 20:36-43. 2020.
- Guise E and Chade AR:
"A validated Boolean model of Microvascular Rarefaction to Predict Treatment Outcomes in Rena; Disease"
Sci Rep. 2020 Jan 16;10(1):440.
- Mahdi F, Chade AR, Bidwell GL:
"Utilizing a Kidney Targeting Peptide to Improve Renal Deposition of a Pro-angiogenic Protein Biopolymer"
Pharmaceutics, 11(10). 2019.
- Engel JE and Chade AR:
" Macrophage polarization in chronic kidney disease: a balancing act between renal recovery or decline?"
Am J Physiol Renal Physiol. 317(6):F1409-F1413. 2019.
- Engel JE, Williams E, Williams ML, Bidwell GL, Chade AR:
"Targeted VEGF therapy induces long-term renal recovery in chronic kidney disease via macrophage polarization ".
Hypertension. 74(5):1113-1123. 2019. (Selected as High Impact Paper-Basic Science 2019)
- Guise E, Engel JE, Williams ML, Mahdi F, Bidwell GL, Chade AR:
"Bioplymer-derived Vascular endothelial Growth Factor Improves Renal Outcomes Following Revascularization".
Am J Physiol Renal Physiol. 1;316(5):F1016-F1025. 2019.
- Lerman LO, Kurtz TW, Touyz RM, Ellison DH, Chade AR, Crowley SD, Mattson DL, Mullins JJ, Osborn J, Eirin A, Reckelhoff JF, Iadecola C, Coffman TM:
“AHA Scientific Statement: Animal Models of Hypertension-A Scientific Statement from the American Heart Association”.
Hypertension. 73(6):e87-e120. 2019.